Market News & Trends
VBL Therapeutics Announces Additional New European Patent
VBL Therapeutics recently announced the European Patent Office (EPO) has granted Patent No. 3328401, which covers VBL’s proprietary investigational anti-MOSPD2 monoclonal antibodies to treat oncology…
First Patient Dosed in Phase 2 Trial to Treat Complications in COVID-19
Arch Biopartners Inc. recently announced it has dosed the first patient in the Phase 2 trial of its lead drug LSALT peptide, targeting prevention of…
PepTC Vaccines Publishes Positive Preclinical Results for COVID-19 Peptide Vaccine
PepTC Vaccines Limited, a subsidiary of Treos Bio Limited, recently announced the publication of positive preclinical results of its investigational PolyPEPI-SCoV-2 peptide vaccine. The study…
Castle Creek Biosciences Treats First Patient in Phase 1/2 Gene Therapy Trial
Castle Creek Biosciences, Inc. recently announced that the first adult patient has been dosed in a Phase 1/2 clinical trial evaluating FCX-013, the company’s investigational…
Beroni Group Announces Successful Completion of SARS-CoV-2 Pseudovirus Neutralization Assay for Treatment of COVID-19
Beroni Group recently announced successful completion of SARS-CoV-2 pseudovirus neutralization assay in collaboration with GenScript Biotech Corporation (HKSE:1548), a leading global biotechnology company. The assay…
Aptose Initiates Dosing of CG-806 in Patients With Acute Myeloid Leukemia
Aptose Biosciences Inc. recently announced dosing of the first patient with acute myeloid leukemia (AML) in a Phase 1 a/b clinical study with CG-806, the…
WHITE PAPER: Outsourcing Analytical Testing for Biologics
Analytical testing required to support CMC activities of biologics is highly sophisticated, and is becoming more so as the modalities of….
WEBINAR ALERT: Stability Testing as Quality Control Measure: Optimizing the Process Throughout the Product Lifecycle
Assessing a compound’s stability is a complex and lengthy process with objectives varying by the development phase…..
MilliporeSigma’s New Platform Speeds Development of Cell & Gene Therapies
MilliporeSigma has recently bolstered its viral vector manufacturing capabilities with the launch of its VirusExpress Lentiviral Production Platform…..
Marinomed Biotech AG Develops First Medicinal Product for Autoimmune Gastritis
Marinomed Biotech AG, a Vienna-based biopharmaceutical company, develops groundbreaking treatment for autoimmune gastritis together with the Medical University of….
Cytovia Therapeutics Partners Enters Research & Licensing Agreement With Inserm
Cytovia Therapeutics recently announced it has entered a research and licensing agreement with Inserm to develop NK engager bi-specific antibodies and iPSC CAR NK cell therapy targeting….
Takeda & Arrowhead Collaborate to Co-Develop & Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
Takeda Pharmaceutical Company Limited and Arrowhead Pharmaceuticals Inc. recently announced a collaboration and licensing agreement to develop ARO-AAT, a Phase 2 investigational RNA interference (RNAi)…
Vaxart Announces Dosing First Subject in Phase 1 Clinical Trial of Its Oral Tablet COVID-19 Vaccine
Vaxart, Inc. recently announced the first subject has been dosed in its Phase 1 study of VXA-CoV2-1, an oral tablet COVID-19 vaccine candidate. “We are…
uniQure Announces Enrollment of Next Two Patients in Phase 1/2 Clinical Trial
uniQure N.V. recently announced that two additional patient procedures have been completed in the Phase 1/2 clinical trial of AMT-130 for the treatment of Huntington’s…
Mogrify Introduces Platform to Systematically Identify Epigenetic Switches Driving Cell Identity & Cell Maintenance
Mogrify Limited recently announced the introduction of EpiMOGRIFY. The platform models the epigenetic state of the cell to predict the switches important for cell identity,…
NapaJen Pharma Reports Positive Results From Phase 1 Clinical Trial of Novel RNAi Therapeutic
NapaJen Pharma, Inc. recently announced positive results from the company’s Phase 1 first-in-human clinical trial of NJA-730. NJA-730 is a novel immunosuppressive therapeutic that combines…
Cambrex Completes Major Expansion of Solid Form Screening Facility
Cambrex recently announced the completion of an expansion of its solid form screening and crystallization process development facility in Edinburgh, Scotland. This major expansion project…
WEBINAR SERIES ALERT - Learn About Complex Parenteral Drug Delivery From Evonik Industry Experts - Free Oct-Nov Webinar Series
As a global CDMO leader for advanced drug delivery, Evonik invites you to join us for a webinar series on parenteral drug delivery. More than a dozen technical experts from Evonik will review….
Scientific Management of Pharmaceutical Container Closure & Delivery Device Compatibility
Diane Paskiet says the relationship between pharmaceutical products and CC/DD is best managed through a rich science-based approach that factors in potential risk and is adapted early in the development process.
Noble & Aptar Pharma Connected Medical Device Solution for Disease Management Adherence & Onboarding Patients
Noble and Aptar Pharma recently announced the launch of AdhereIT - a connected, intuitive, and user-friendly onboarding solution for the growing number of patients with…
